Centre for Cancer Biomarkers CCBIO

CCBIO SAB (Scientific Advisory Board)

The CCBIO Scientific Advisory Board (SAB) consists of professors Carl-Henrik Heldin, Bruce Zetter and Ate van der Zee, all three being internationally leading researchers in CCBIO-relevant fields.

Group photo of Ate Van der Zee, Carl-Henrik Heldin and Bruce Zetter.
Ingvild Melien

Main content

Short bios of each SAB representative can be found at the bottom of this page.

The CCBIO Scientific Advisory Board (SAB) consists of Professors Carl Henrik Heldin (chair), Bruce Zetter and Ate van der Zee, all three being internationally leading researchers in CCBIO-relevant fields. The SAB’s mandate is to give the center director and center staff advice on science and scientific matters. Usually, the SAB convenes once a year for a full day meeting with CCBIO’s investigators, mostly in connection with the CCBIO Annual Symposium. The feedback from the SAB has been of great inspiration and utility to CCBIO. Preceding every SAB meeting, CCBIO provides the SAB a report on its response to their previous recommendations. The CCBIO SAB convened in-person in Bergen on June 3, 2022.

In their 2022 report, the SAB stated being very much impressed with the development of CCBIO, both in terms of its high scientific production, its extensive training programs, and dissemination efforts. They consider CCBIO to have a strong leadership who has managed to bring together scientists with complementary skills to build a strong collaborative community, creating a vibrant scientific atmosphere.

The SAB was reassured by the fact that CCBIO, despite the sequela of the pandemic, has been able to retain the motivation and enthusiasm for highlevel translation of findings from the lab to the clinic. CCBIO’s large number of clinical trials, in particular in leukemias, gynecological cancers, prostate cancer and melanoma, speaks for this. The SAB was impressed by the work of the new junior faculty members Carina Strell and Agnete Engelsen, their work being highly collaborative and synergistic with other CCBIO members, and a significant potential for the future. Further, the inclusion of an Ethics and Economics program is a unique strength of CCBIO, e.g. influencing members of the center and others to reflect on their work in a broader context of societal impact. The ability to get easy access to high-level support in application of bioinformatics analyses remains a problem managed by the CCBIO scientists by forming research collaborations with bioinformatics environments.

Moreover, CCBIO researchers are involved in extensive training and teaching programs. CCBIO’s excellent Research School for Cancer Studies has a series of important courses, the newly established course in medical innovation being an especially commendable recent addition. Educational efforts such as these represent a significant strength and provide a clear advantage to CCBIO’s younger members. The CCBIO Masterclass, aimed at training promising young future group leaders, is very well received by the SAB. They believe that this is something that could potentially be expanded with benefit to junior faculty in other programs at the University of Bergen.

The SAB enthusiastically supports the continued development of these efforts and recommends that CCBIO’s educational efforts be further supported by the University of Bergen as it represents a jewel in the crown of the wider university.

Through its impressive annual report, newsletters and general outreach through the media, CCBIO has made extensive efforts to reach out to both the scientific community and the general public, providing information about its findings and activities.

In brief summary, CCBIO’s first 9 years have seen an excellent research environment being established and continuously developed, with a strong collaborative consortium of skilled scientists with complementary expertise and performing excellent basic, translational and clinical science; their research efforts have resulted in a large number of important publications and excellent educational and training activities.

Short bio,  Heldin

Carl-Henrik Heldin is the chairman of CCBIO’s SAB and is professor in molecular cell biology at Uppsala University, and chairman of the Nobel Foundation. 
Professor Heldin was born in 1952 and obtained a PhD degree in medical and physiological chemistry in 1980 at the University of Uppsala, where he continued to work until 1985 in a position sponsored by the Swedish Cancer Society. Between 1986 and 2017 he was the branch director of the Ludwig Institute for Cancer Research in Uppsala, Sweden, and since 1992 he is professor in molecular cell biology at Uppsala University. Professor Heldin is a member of several learned societies, including the European Molecular Biology Organization, the Royal Swedish Academy of Sciences, Academia Europea and Japan Academy, and he is an honorary doctor at the universities of Patras, Helsinki, Turku and Heidelberg.
He serves or has served on the scientific advisory boards for several companies and academic institutions, including the German Cancer Center, Heidelberg, Max Planck Institute for Biochemistry, Martinsried, Center for Molecular Medicine, Vienna, European Molecular Biology Laboratory, Heidelberg, Institute for Cancer Research, Oslo, and now also CCBIO. Professor Heldin was vice president of the European Research Council until 2014, and chair of EMBO Council until 2020.
Professor Heldin has received several scientific awards, including the Prix Antoine Lacassagne (1989), K. Fernströms Large Medical Prize (1993), the Pezcoller-American Association for Cancer Research Award (2002), and Anders Jahre´s Large Medical Prize (2019).

Short bio, van der Zee

Ate van der Zee is Chairman of the Board of Directors and professor of Gynaecological Oncology at the University Medical Center Groningen (UMCG).

Professor van der Zee was born in 1960, graduated from university of Groningen as a doctor of medicine (cum laude) and obtained a PhD (cum laude) focused on Translational Research in Ovarian Cancer at the Faculty of Medical Sciences, University of Groningen, where he has also been head of the Department of Gynecologic Oncology and chairman of the Medical Board.

Professor Van der Zee serves and has served on various national and international advisory and program committees / Boards, including Dutch Cancer Society, NCRN UK, NCI USA, IGCS, ESGO, DHD, CGS and the General Board of the Capacity Body of behalf of the Dutch Federation of University Medical Centers. He is past President of the European Society for Gynecologic Oncology (2009 – 2011) and past president of the Dutch Working Party for Gynecologic Oncology. In 2017 he received the Innovation Award from the Society of Gynecologic Oncology USA.

Further, he has established a managed clinical network for ovarian cancer for all hospitals in the North-East of the Netherlands to improve the care for ovarian cancer patients and which forms a unique platform for translational research.

His current research focuses on translational and clinical research in vulvar cancer. Together with Dr. Oonk he leads a world wide consortium (GROINSS-V), which performs landmark clinical studies in vulvar cancer.

Ate van der Zee combines his current chairman position with clinical work and academic research.

Short bio, Zetter

Bruce Zetter is the Charles Nowiszewski Professor of Cancer Biology at Harvard Medical School and Boston Children’s Hospital, Boston, MA, USA. Professor Zetter was born in 1946 and obtained his PhD from the University of Rhode Island in 1974. He has been vice president of research and chief scientific officer at Boston Children’s Hospital.

Professor Zetter is frequently sought as an advisor on science and business practice to industry executives and scientists. He has served as consultant or scientific advisory board member to more than 30 biotechnology and pharmaceutical companies, venture firms and investment firms and academic institutions. Further, he also serves on several grant review boards for public agencies such as the American Heart Association and the American Cancer Society, and currently also serves on the editorial board of 8 peer-reviewed journals. In addition, he is often called on as an expert witness in court cases involving health and biotechnology.

As a frequent lecturer, he has given over 300 lectures to universities, conferences and businesses. He has also won numerous national and international awards for his work in the field of cancer research including a Faculty Research Award from the American Cancer Society and the prestigious MERIT award from the US National Cancer Institute and a Creativity Award from the Prostate Cancer Foundation. He has also received three teaching awards from the students at Harvard Medical School for excellence as a teacher and as a course director. In November 2019, he was also appointed as Honorary Doctor at the University of Bergen, Faculty of Medicine.